GSK plc (LON:GSK) Insider Purchases £9,147.46 in Stock

GSK plc (LON:GSK) insider Elizabeth (Liz) McKee Anderson purchased 446 shares of GSK stock in a transaction dated Monday, September 23rd. The shares were purchased at an average cost of GBX 2,051 ($27.46) per share, for a total transaction of £9,147.46 ($12,248.88).

GSK Trading Up 0.2 %

GSK stock traded up GBX 3 ($0.04) during midday trading on Tuesday, reaching GBX 1,530.50 ($20.49). 7,509,878 shares of the stock traded hands, compared to its average volume of 10,484,249. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The firm has a market cap of £62.44 billion, a PE ratio of 1,351.77, a price-to-earnings-growth ratio of 1.34 and a beta of 0.31. The company has a 50-day simple moving average of GBX 1,583.06 and a two-hundred day simple moving average of GBX 1,631.08. GSK plc has a 12-month low of GBX 1,371.40 ($18.36) and a 12-month high of GBX 1,823.50 ($24.42).

GSK Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, October 10th. Investors of record on Thursday, August 15th will be issued a GBX 15 ($0.20) dividend. This represents a dividend yield of 0.97%. The ex-dividend date is Thursday, August 15th. GSK’s dividend payout ratio (DPR) is currently 5,309.73%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GSK shares. Shore Capital restated a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Citigroup reduced their price objective on shares of GSK from GBX 2,120 ($28.39) to GBX 1,900 ($25.44) and set a “buy” rating on the stock in a report on Friday, July 5th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Monday, July 29th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 ($28.12) price target on shares of GSK in a research report on Thursday, June 27th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 1,820 ($24.37) price objective on shares of GSK in a report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.71 ($24.18).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.